Scisparc Ltd - Asset Resilience Ratio
Scisparc Ltd (SPRC) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Scisparc Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Scisparc Ltd's Asset Resilience Ratio has changed over time. See Scisparc Ltd (SPRC) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Scisparc Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Scisparc Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Scisparc Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Scisparc Ltd Industry Peers by Asset Resilience Ratio
Compare Scisparc Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Crispr Therapeutics AG
NASDAQ:CRSP |
Biotechnology | 74.05% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
Annual Asset Resilience Ratio for Scisparc Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Scisparc Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.00% | $517.00K | $10.35 Million | -21.83pp |
| 2023-12-31 | 26.83% | $3.00 Million | $11.18 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $10.61 Million | -- |
| 2010-12-31 | 51.47% | $5.14 Million | $9.98 Million | +1.74pp |
| 2009-12-31 | 49.73% | $6.08 Million | $12.22 Million | +11.90pp |
| 2008-12-31 | 37.83% | $3.79 Million | $10.01 Million | +2.63pp |
| 2007-12-31 | 35.20% | $5.36 Million | $15.22 Million | -10.06pp |
| 2006-12-31 | 45.26% | $5.08 Million | $11.22 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more